NERVMinerva Neurosciences, Inc.

Nasdaq minervaneurosciences.com


$ 2.49 $ -0.02 (-0.8 %)    

Thursday, 18-Apr-2024 11:38:00 EDT
QQQ $ 414.59 $ -8.76 (-2.07 %)
DIA $ 379.83 $ 1.96 (0.52 %)
SPY $ 494.96 $ -4.36 (-0.87 %)
TLT $ 89.15 $ 0.32 (0.36 %)
GLD $ 221.02 $ 0.69 (0.31 %)
$ 2.48
$ 2.49
$ 2.42 x 100
$ 0.00 x 0
$ 2.49 - $ 2.49
$ 2.26 - $ 13.49
11,385
na
16.14M
$ 0.71
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-22-2024 12-31-2023 10-K
2 11-07-2023 09-30-2023 10-Q
3 08-01-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-08-2023 12-31-2022 10-K
6 11-09-2022 09-30-2022 10-Q
7 08-09-2022 06-30-2022 10-Q
8 05-04-2022 03-31-2022 10-Q
9 03-01-2022 12-31-2021 10-K
10 11-08-2021 09-30-2021 10-Q
11 08-02-2021 06-30-2021 10-Q
12 05-12-2021 03-31-2021 10-Q
13 03-08-2021 12-31-2020 10-K
14 11-02-2020 09-30-2020 10-Q
15 08-03-2020 06-30-2020 10-Q
16 05-04-2020 03-31-2020 10-Q
17 03-09-2020 12-31-2019 10-K
18 11-04-2019 09-30-2019 10-Q
19 08-05-2019 06-30-2019 10-Q
20 05-06-2019 03-31-2019 10-Q
21 03-12-2019 12-31-2018 10-K
22 11-05-2018 09-30-2018 10-Q
23 08-02-2018 06-30-2018 10-Q
24 05-03-2018 03-31-2018 10-Q
25 03-12-2018 12-31-2017 10-K
26 11-06-2017 09-30-2017 10-Q
27 08-03-2017 06-30-2017 10-Q
28 05-04-2017 03-31-2017 10-Q
29 03-13-2017 12-31-2016 10-K
30 11-03-2016 09-30-2016 10-Q
31 08-04-2016 06-30-2016 10-Q
32 05-03-2016 03-31-2016 10-Q
33 03-14-2016 12-31-2015 10-K
34 11-05-2015 09-30-2015 10-Q
35 08-05-2015 06-30-2015 10-Q
36 05-07-2015 03-31-2015 10-Q
37 03-26-2015 12-31-2014 10-K
38 11-06-2014 09-30-2014 10-Q
39 08-07-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 minerva-neurosciences-on-april-10-got-notice-from-nasdaq-that-company-was-not-in-compliance-with-nasdaqs-listing-rule

-SEC Filing

 dow-dips-over-100-points-jm-smucker-posts-upbeat-earnings

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 100 points on Tuesday. The Dow ...

 why-helix-energy-solutions-shares-are-trading-lower-by-11-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.

 regulatory-setback-for-minerva-neurosciences-schizophrenia-treatment-candidate-fda-asks-for-more-data

Minerva Neurosciences faces FDA challenges for roluperidone in schizophrenia treatment. Understand the clinical deficiencies an...

 hc-wainwright--co-reiterates-neutral-on-minerva-neurosciences-maintains-11-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Minerva Neurosciences (NASDAQ:NERV) with a Neutral and maintains $11...

 crude-oil-gains-1-macys-plans-to-close-150-stores

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 150 points on Tuesday. The Dow traded...

 nasdaq-rises-50-points-lowes-earnings-top-views

U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 50 points on Tuesday. Following the market ope...

 minerva-neurosciences-receives-complete-response-letter-from-fda-for-new-drug-application-for-roluperidone-for-treatment-of-negative-symptoms-in-patients-with-schizophrenia-due-to-clinical-deficiencies

In the CRL, the FDA cited the following clinical deficiencies:Although one study (MIN-101C03) demonstrated statistical signific...

 minerva-neurosciences-q4-eps-119-misses-088-estimate-cash-cash-equivalents-and-restricted-cash-were-approximately-41m

Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(1.19) per share which missed the analyst consensus estimate ...

 hc-wainwright--co-maintains-neutral-on-minerva-neurosciences-raises-price-target-to-11

HC Wainwright & Co. analyst Douglas Tsao maintains Minerva Neurosciences (NASDAQ:NERV) with a Neutral and raises the pri...

 minerva-neurosciences-q2-eps-112-misses-044-estimate-cash-cash-equivalents-and-restricted-cash-of-519m

Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(1.12) per share which missed the analyst consensus estimate ...

 10-short-squeeze-stocks-to-watch-baosheng-media-toro-corp-getty-images-and-more

Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for th...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION